knowledge logo

BEI Resources Knowledge Base


Search Our Knowledge Base

The Knowledge Base is an informational database assembled by our Support Specialists and Scientific Staff which provides additional knowledge about the BEI Resources program and reagents through questions and answers. In order to use the Knowledge Base, enter a keyword or phrase that best describes the information of interest. More >>
   

Showing 1 to 5 of 16 Results1234
What is the Emergency Use Simple Letter Agreement (EUSLA)?

The  Emergency Use Simple Letter Agreement  outlines the terms in which SARS-CoV-2 materials are being provided.  In light of the emergence of the novel coronavirus, 2019-SARS-CoV-2, and urgent need to mitigate the pathogen&rsquo s spread, the  EUSLA  was instituted for the provision of these materials under the terms outlined in the agreement. The  EUSLA  is not negotiable.

Author: BEI Resources
0 Comments
Rating:
Updated on: 4/27/2022 1:07:40 PM
What level of registration do I need to receive SARS-CoV-2 materials?

Each product on the BEI Resources website lists a BEI Resources level of registration. Interested researchers will need to ensure they are registered at the appropriate level to receive materials. Please click here for registration instructions. If you need to upgrade your registration to a higher level, please click here for instructions.

Author: BEI Resources
0 Comments
Rating:
Updated on: 4/27/2022 1:26:40 PM
How much do SARS-CoV-2 materials cost?

All BEI Resources reagents, including SARS-CoV-2 materials,  are provided world-wide at  no cost. While there is no cost for the reagents themselves, additional shipping and handling charges may apply and will display in the shopping cart if applicable.

Author: BEI Resources
0 Comments
Rating:
Updated on: 4/27/2022 1:27:06 PM
Can I commercialize SARS COV-2 materials?

Material as used in this answer, means the original material or any unmodified progeny received from BEI Resources. SARS-CoV-2 materials received under the  EUSLA  are made available for any legitimate purpose, including commercial purposes, as long as they are to rapidly prevent, detect, prepare for, and respond to, the spread or transmission of the 2019 SARS-CoV-2. Any transfer of the original material or any unmodified progeny must be done under the terms of the  EUSLA  (see question above regarding transfer of SARS-CoV-2 materials). Any products made by you, that are not considered the original material or unmodified progeny, are excluded from this requirement, and you are free to share and commercialize those products as your own products.

Author: BEI Resources
0 Comments
Rating:
Updated on: 4/27/2022 1:27:24 PM
Who is qualified to receive SARS-CoV-2 materials?

Registration  with BEI Resources is required to request SARS-CoV-2 materials. BEI Resources reagents are shared with registered individuals and organizations doing research on Emerging Infections and other relevant areas of interest related to Microbiology. To register you must be affiliated with a public, private, academic, non-profit or for-profit institution. Registrants must demonstrate they work in an established institution with facilities and safety programs appropriate for the Level of registration requested.

Author: BEI Resources
0 Comments
Rating:
Updated on: 4/18/2022 8:40:41 AM
Showing 1 to 5 of 16 Results1234

Showing 1 to 5 of 9 Results12
SARS Virus Now Available for Researchers
We have available for the first time in the BEI Resources catalog, two SARS Coronaviruses (SARS-CoV) derived from the Urbani strain. NR-18925 is produced from a recombinant infectious clone, icSARS-CoV. NR-15418 is the mouse-adapted strain, Urbani v2163, developed by Dr. Barnard as a lethal model fo ...
Author: BEI Resources
0 Comments
Rating:
Updated on: 12/4/2018 2:36:38 PM
Sand Flies, Reduviids and Ticks are Here!
BEI Resources announces the addition of Sand Flies, Reduviids and Ticks for the research community. Catalog Number Vector Pathogen Competence   NR-43999 Phlebotomus papatasi, PPNS, Larval Leishmania major and Sand Fly Fever phleboviruses.   NR-44000 Phlebotomus papata ...
Author: BEI Resources
0 Comments
Rating:
Updated on: 12/4/2018 2:32:27 PM
Development of let digital PCR for the detection of Babesia microti and Babesia duncani
Development of let digital PCR for the detection of Babesia microti and Babesia duncani Babesia spp. are obligate protozoan parasites of red blood cells. Transmission to humans occurs through bites from infected ticks or blood transfusion. Infections with B. microti account for the majority of the ...
Author: BEI Resources
0 Comments
Rating:
Updated on: 12/9/2014 10:58:36 AM
Mycobacterium tuberculosis Production Manuals & SOP's from Dr. Karen Dobos
Please use this link  to find a comprehensive list of  protocols and SOPs for Mycobacterium tuberculosis including: Large Scale Growth Subcellular Fractions Preparation and Fractionation of Cell Wall Proper Lipoarabinomannan (LAM) and Lipomannan (LM) Antibodies Microarrays Media Native Ma ...
Author: BEI Resources
0 Comments
Rating:
Updated on: 11/20/2014 11:18:21 AM
BEI Resources Fungi Catalog is Growing!
  BEI Resources is working to expand the fungal catalog so that researchers have a broader range of organisms and reagents for their work.  BEI Resources currently has eight genus and species represented with several more currently going through the production pipeline.  BEI Resources i ...
Author: BEI Resources
0 Comments
Rating:
Updated on: 8/29/2014 9:49:43 AM
Showing 1 to 5 of 9 Results12
The following is a list of published abstracts and papers where the work was either facilitated, or directly supported, by the BEI Resources Program.


Showing 1 to 5 of 9772 Results12345678910...>>
Sun, J., Development of Molecular Transporter Platforms for the Delivery of Clinically Relevant Antibiotics and Genes. 2024, Stanford University.
Author: BEI Resources
Updated on: 12/9/2024 2:22:28 PM
Zhu, F., et al., CYP3A4-mediated metabolism of artemisinin to 10β-hydroxyartemisinin with comparable anti-malarial potency. Malaria Journal, 2024. 23(1): p. 1-9.
Author: BEI Resources
Updated on: 12/9/2024 2:21:57 PM
Zhou, N.E., et al., An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo. Cell Reports, 2024. 43(11).
Author: BEI Resources
Updated on: 12/9/2024 2:21:27 PM
Zhou, B., et al., Prophages divert Staphylococcus aureus defenses against host lipids. Journal of Lipid Research, 2024: p. 100693.
Author: BEI Resources
Updated on: 12/9/2024 2:21:14 PM
Ye, G., et al., Discovery of Nanosota-9 as anti-Omicron nanobody therapeutic candidate. PLoS pathogens, 2024. 20(11): p. e1012726.
Author: BEI Resources
Updated on: 12/9/2024 2:21:01 PM
Showing 1 to 5 of 9772 Results12345678910...>>
The following is a list of published abstracts and papers where the work was either facilitated, or directly supported, by the NIH HIV Reagent Program.



Showing 1 to 5 of 1042 Results12345678910...>>
Author: HIV
Updated on: 3/28/2024 8:38:45 PM

2009 - 2011 Journal Citations

Author: HIV
Updated on: 3/28/2024 8:38:45 PM

2006 - 2008 Journal Citations

Author: HIV
Updated on: 3/28/2024 8:38:45 PM

2003 - 2005 Journal Citations

Author: HIV
Updated on: 3/28/2024 8:38:45 PM

2000 - 2002 Journal Citations

Author: HIV
Updated on: 3/28/2024 8:38:45 PM
Showing 1 to 5 of 1042 Results12345678910...>>


Sorry, there are no questions found for the search criteria at this time.